Market: NASD |
Currency: USD
Address: Four Tower Bridge
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
📈 Madrigal Pharmaceuticals, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$459.40
-
Upside/Downside from Analyst Target:
8.08%
-
Broker Call:
27
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
25-50%
-
Net Income Growth Range (1Y):
25-50%
-
Revenue Growth Range (1Y):
>500%
-
Upcoming Earnings Date:
2025-10-30
-
EPS Estimate:
-2.06
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2016 |
- |
$0.028571 |
- |
2016-07-25 |
- |
Stock split |
|
Total Amount for 2016: $0.028571 |
📅 Earnings & EPS History for Madrigal Pharmaceuticals, Inc.
| Date | Reported EPS |
|---|
| 2025-10-30 (estimated upcoming) | - |
| 2025-08-05 | -1.9 |
| 2025-05-01 | -3.32 |
| 2025-02-26 | -2.71 |
| 2024-10-31 | -4.92 |
| 2024-08-07 | -7.1 |
| 2024-05-07 | -7.38 |
| 2024-02-28 | -5.68 |
| 2023-11-06 | -5.34 |
| 2023-08-08 | -4.69 |
| 2023-05-09 | -4.23 |
| 2023-02-23 | -4.98 |
| 2022-11-03 | -4.75 |
| 2022-08-04 | -4.14 |
| 2022-05-09 | -3.36 |
| 2022-02-24 | -3.79 |
| 2021-11-04 | -3.79 |
| 2021-08-05 | -3.72 |
| 2021-05-06 | -3.32 |
| 2021-02-25 | -3.82 |
| 2020-11-05 | -3.75 |
| 2020-08-06 | -3.18 |
| 2020-05-07 | -2.34 |
| 2020-02-26 | -1.8 |
| 2019-11-06 | -1.39 |
📰 Related News & Research
No related articles found for "madrigal pharmaceuticals".
